Sachs David C. 4
4 · ImmunityBio, Inc. · Filed Feb 2, 2024
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-01-31+70,745→ 212,673 total - Exercise/Conversion
Restricted Stock Units
2024-01-31−70,745→ 0 total→ Common Stock (70,745 underlying) - Tax Payment
Common Stock
2024-01-31$3.36/sh−26,835$90,166→ 185,838 total
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F2]Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares vested on January 31, 2024.